NR4A1 and triple-negative breast carcinoma: To test this hypothesis, we examined LXR expression in different breast cancer subtypes and determined the metabolic and anti-tumor effects of 1E5 in cellular models of hormone receptor-positive luminal A, endocrine-resistant, and triple-negative breast cancers.